US 12,064,650 B2
Ultrasound therapy system
Azita Soltani, Snohomish, WA (US); and Adrian F. Prokop, Seattle, WA (US)
Assigned to EKOS CORPORATION, Bothell, WA (US)
Filed by EKOS CORPORATION, Bothell, WA (US)
Filed on Jul. 13, 2021, as Appl. No. 17/374,524.
Application 13/176,613 is a division of application No. 11/739,629, filed on Apr. 24, 2007, abandoned.
Application 17/374,524 is a continuation of application No. 16/268,075, filed on Feb. 5, 2019, granted, now 11,058,901, issued on Jul. 13, 2021.
Application 16/268,075 is a continuation of application No. 13/176,613, filed on Jul. 5, 2011, granted, now 10,232,196, issued on Mar. 19, 2019.
Claims priority of provisional application 60/799,119, filed on May 9, 2006.
Claims priority of provisional application 60/794,330, filed on Apr. 24, 2006.
Prior Publication US 2021/0339055 A1, Nov. 4, 2021
Int. Cl. A61B 8/00 (2006.01); A61B 17/22 (2006.01); A61M 25/00 (2006.01); A61M 37/00 (2006.01); A61N 7/02 (2006.01)
CPC A61N 7/022 (2013.01) [A61B 17/2202 (2013.01); A61M 25/0032 (2013.01); A61M 37/0092 (2013.01); A61B 2017/22088 (2013.01); A61B 2017/22089 (2013.01); A61M 25/003 (2013.01); Y10T 29/49826 (2015.01)] 20 Claims
OG exemplary drawing
 
16. A method of treating a vascular occlusion, the method comprising:
positioning an ultrasound catheter within a patient, the ultrasound catheter including a treatment zone, an ultrasound radiating member positioned within the treatment zone, and a fluid delivery lumen hydraulically coupled to an exit port within the treatment zone;
delivering, through the fluid delivery lumen and the exit port, a microbubble therapeutic compound to the internal portion of the vascular occlusion at an infusion rate that is in the range of 100 mL per hour to 120 mL per hour, the microbubble therapeutic compound having a microbubble concentration in the range of 8×106 to 12×109 microbubbles per milliliter, wherein the microbubble therapeutic compound is selected from the group consisting of neuroprotection compounds, anti-thrombosis compounds, heparin, urokinase, streptokinase, tissue plasminogen activator (tPA), and recombinant tissue plasminogen activator (rtPA); and
delivering ultrasonic energy to the vascular occlusion, wherein the ultrasonic energy causes cavitation to occur within the microbubble therapeutic compound delivered to the vascular occlusion.